165804-10-4

Upstream product

• 1026483-72-6 2-methyl-2-[4-(8-oxo-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-butyl]-malonic acid dibenzyl ester 
• 72079-77-7 6,7-dihydroimidazo<4,5-d><1,3>diazepin-8(3H)-one 
• 165801-42-3 2-[4-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-butyl]-2-methyl-malonic acid dibenzyl ester 

Downstream Products

• 273224-10-5 2-benzylcarbamoyl-6-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-2-methyl-hexanoic acid benzyl ester 
• 1025927-26-7 6-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-2-methyl-2-phenethylcarbamoyl-hexanoic acid benzyl ester 
• 165804-11-5 6-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-2-methyl-2-phenylcarbamoyl-hexanoic acid benzyl ester 

Relevant academic research and scientific papers

AMP deaminase inhibitors. 4. Further N3-substituted coformycin aglycon analogues: N3-alkylmalonates as ribose 5'-monophosphate mimetics

AMP deaminase (AMPDA) inhibitors increase the levels of extracellular adenosine and preserve intracellular adenylate pools in cellular models of ATP depletion and therefore represent a potential new class of antiischemic drugs. Recently we reported that r